MA46500A1 - Nouvelles combinaisons d'un antagoniste h3 et d'un inhibiteur de reuptake de noradrenaline, et leurs utilisations therapeutiques - Google Patents

Nouvelles combinaisons d'un antagoniste h3 et d'un inhibiteur de reuptake de noradrenaline, et leurs utilisations therapeutiques

Info

Publication number
MA46500A1
MA46500A1 MA46500A MA46500A MA46500A1 MA 46500 A1 MA46500 A1 MA 46500A1 MA 46500 A MA46500 A MA 46500A MA 46500 A MA46500 A MA 46500A MA 46500 A1 MA46500 A1 MA 46500A1
Authority
MA
Morocco
Prior art keywords
antagonist
therapeutic uses
reuptake inhibitor
norepinephrine reuptake
new combinations
Prior art date
Application number
MA46500A
Other languages
English (en)
Other versions
MA46500B1 (fr
Inventor
Xavier Ligneau
Laurent Landais
David Perrin
Jeanne Marie Lecomte
Jean Charles Schwartz
Original Assignee
Bioprojet Soc Civ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioprojet Soc Civ filed Critical Bioprojet Soc Civ
Publication of MA46500A1 publication Critical patent/MA46500A1/fr
Publication of MA46500B1 publication Critical patent/MA46500B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/092—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings with aromatic radicals attached to the chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des combinaisons d'un antagoniste h3 et d'un antidépresseur, qui présentent une activité synergique favorisant le sillage.
MA46500A 2018-07-27 2019-07-26 Nouvelles combinaisons d'un antagoniste h3 et d'un inhibiteur de reuptake de noradrenaline, et leurs utilisations therapeutiques MA46500B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18306017.7A EP3598975B1 (fr) 2018-07-27 2018-07-27 Nouvelles combinaisons d'un antagoniste h3 et un inhibiteur de la recapture de la noradrénaline et leurs utilisations thérapeutiques

Publications (2)

Publication Number Publication Date
MA46500A1 true MA46500A1 (fr) 2021-01-29
MA46500B1 MA46500B1 (fr) 2022-07-29

Family

ID=63144936

Family Applications (1)

Application Number Title Priority Date Filing Date
MA46500A MA46500B1 (fr) 2018-07-27 2019-07-26 Nouvelles combinaisons d'un antagoniste h3 et d'un inhibiteur de reuptake de noradrenaline, et leurs utilisations therapeutiques

Country Status (19)

Country Link
US (2) US11229632B2 (fr)
EP (1) EP3598975B1 (fr)
JP (1) JP7509520B2 (fr)
KR (1) KR102841963B1 (fr)
CN (1) CN110772515A (fr)
AU (1) AU2019208166B2 (fr)
BR (1) BR102019015415A2 (fr)
CA (1) CA3050590A1 (fr)
DK (1) DK3598975T3 (fr)
ES (1) ES2840253T3 (fr)
HU (1) HUE052652T2 (fr)
IL (1) IL268208B (fr)
MA (1) MA46500B1 (fr)
MX (1) MX379400B (fr)
PL (1) PL3598975T3 (fr)
PT (1) PT3598975T (fr)
TN (1) TN2019000216A1 (fr)
TW (2) TWI887204B (fr)
ZA (1) ZA201904876B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3378858A1 (fr) * 2017-03-21 2018-09-26 Bioprojet Tétrahydrate de ligand h3, son procédé de préparation et compositions pharmaceutiques le comprenant
JP7234955B2 (ja) 2020-01-31 2023-03-08 トヨタ自動車株式会社 車両
WO2022159629A1 (fr) * 2021-01-20 2022-07-28 Alto Neuroscience, Inc. Stratégie de combinaison de médicaments pour le traitement des troubles psychiatriques et neurologiques dans lesquels il existe une anhédonie ou un dysfonctionnement lié à la motivation
US20240398777A1 (en) * 2023-06-01 2024-12-05 Harmony Biosciences, Llc Method of treating symptoms of prader-willi syndrome
WO2025082974A1 (fr) * 2023-10-16 2025-04-24 Bioprojet Pharma Nouvelles formulations de pitolisant et procédés d'utilisation
WO2025162430A1 (fr) * 2024-02-01 2025-08-07 重庆罗特司光电科技有限公司 Combinaison de médicaments et son utilisation dans la prévention ou le traitement d'une maladie neurodégénérative
WO2025207664A1 (fr) * 2024-03-25 2025-10-02 Axsome Therapeutics, Inc. Utilisation de réboxétine pour traiter la narcolepsie
US12565478B1 (en) 2025-01-21 2026-03-03 Axsome Therapeutics, Inc. (S)-2-((S)-(2-ethoxyphenoxy)(phenyl)methyl)-4-nitrosomorpholine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0982300A3 (fr) 1998-07-29 2000-03-08 Societe Civile Bioprojet Non-imidazole alkylamines comme antagonistes du recepteur histamine H3 et leur application thérapeutique
EP1717233A1 (fr) 2005-04-29 2006-11-02 Bioprojet Ligands du récepteur histaminique H3 et leur application thérapeutique
EP1717235A3 (fr) 2005-04-29 2007-02-28 Bioprojet Phenoxypropylpiperidines and -pyrrolidines et leur utilisation comme ligands du récepteur histaminique H3
EP1717234A1 (fr) 2005-04-29 2006-11-02 Bioprojet Phenoxypropylpiperidines and -pyrrolidines et leur utilisation comme ligands du récepteur histaminique H3
EP3239138A1 (fr) * 2016-04-25 2017-11-01 Sandoz Ag Sel de fumarate d'hydrogène de 1-[3-[3-(4-chlorophényl)propoxy]propyl]pipéridine
EP3378477A1 (fr) 2017-03-21 2018-09-26 BIOPROJET Pharma Nouvelles utilisations thérapeutiques de ligands h3
EP3378858A1 (fr) 2017-03-21 2018-09-26 Bioprojet Tétrahydrate de ligand h3, son procédé de préparation et compositions pharmaceutiques le comprenant

Also Published As

Publication number Publication date
AU2019208166B2 (en) 2024-08-01
IL268208B (en) 2022-09-01
TWI905542B (zh) 2025-11-21
KR20200012781A (ko) 2020-02-05
JP7509520B2 (ja) 2024-07-02
BR102019015415A2 (pt) 2020-01-28
HUE052652T2 (hu) 2021-05-28
EP3598975B1 (fr) 2020-10-21
CN110772515A (zh) 2020-02-11
DK3598975T3 (da) 2020-11-02
US20220079932A1 (en) 2022-03-17
TN2019000216A1 (en) 2021-01-07
RU2019123563A (ru) 2021-01-26
US11229632B2 (en) 2022-01-25
JP2020015724A (ja) 2020-01-30
ES2840253T3 (es) 2021-07-06
EP3598975A1 (fr) 2020-01-29
PL3598975T3 (pl) 2021-04-19
ZA201904876B (en) 2020-05-27
PT3598975T (pt) 2020-12-21
KR102841963B1 (ko) 2025-08-04
TWI887204B (zh) 2025-06-21
IL268208A (en) 2019-11-28
TW202007395A (zh) 2020-02-16
AU2019208166A1 (en) 2020-02-13
MX2019008637A (es) 2020-01-28
MX379400B (es) 2025-03-11
US20200030310A1 (en) 2020-01-30
US12059416B2 (en) 2024-08-13
CA3050590A1 (fr) 2020-01-27
TW202404587A (zh) 2024-02-01
MA46500B1 (fr) 2022-07-29

Similar Documents

Publication Publication Date Title
MA46500A1 (fr) Nouvelles combinaisons d'un antagoniste h3 et d'un inhibiteur de reuptake de noradrenaline, et leurs utilisations therapeutiques
BR112021024108A2 (pt) Inibidores de tead e usos dos mesmos
CR20230077A (es) Mezclas fungicidas
EA202190377A9 (ru) Композиции ингибиторов cxcr4 и способы получения и применения
BR112018006259A2 (pt) "adjunto compressível com estruturas de suporte intermediárias"
MX391414B (es) Compuesto novedoso de bifenilo o sal del mismo.
MX2020010828A (es) Composiciones y métodos para el tratamiento de la sobrecarga de hierro.
NI202100018A (es) Moduladores de la expresión de pnpla3
HRP20251693T1 (hr) Poboljšana sinteza 1,4-diazaspiro[5.5]undekan-3-ona
EA201792000A1 (ru) Ингибиторы грелин-o-ацилтрансферазы
MX2020005483A (es) Antagonistas de ildr2 y combinaciones de los mismos.
EP3701946A4 (fr) Composition destinée à prévenir ou à traiter des maladies neurodégénératives, contenant un composé à base de diterpène
EA201992117A1 (ru) Фармацевтическая комбинация, содержащая понесимод
UY37560A (es) Combinación de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta
JOP20210108A1 (ar) معدِّلات تعبير irf5
MX376853B (es) Odorante osmanthus.
MX2019000919A (es) Combinacion de un inhibidor de bcl-2 y un inhibidor de mcl1, usos y composiciones farmaceuticas de estos.
EP4017973A4 (fr) Biosynthèse d'ériodictyol
MA54222A (fr) Combinaison d'un inhibiteur de mcl-1 et de midostaurine, utilisations et compositions pharmaceutiques associées
EP3972598A4 (fr) Nouvelles utilisations du crénolanib
CO2019007261A2 (es) Combinación de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta
EP3911656C0 (fr) Synthèse de 14-méthyl-16-oxabicyclo[10.3.1] hexadéc-12-ène
UA45476S (uk) 1.-3. годинник наручний
EP3976029A4 (fr) Inhibiteurs d'asparagine endopeptidase (aep), compositions et utilisations associées
UA46550S (uk) 1.-2. шампур